

(43) International Publication Date
18 September 2014 (18.09.2014)

(51) International Patent Classification:

C07D 498/22 (2006.01) A61K 31/519 (2006.01)
A61K 31/437 (2006.01) A61P 31/14 (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/US2014/029765

(22) International Filing Date:

14 March 2014 (14.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/798,961 15 March 2013 (15.03.2013) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: BJORNSON, Kyla; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). KARKI, Kapil K.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). LINK, John O.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). PYUN, Hyung-Jung; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). SCHRIER, Adam J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). STEVENS, Kirk L.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). TAYLOR, James G.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). VIVI-AN, Randall W.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). ZABLOCKI,

Jeff; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). ZIPFEL, Sheila; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).


(74) Agents: TANNER, Lorna L. et al.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS



(57) Abstract: Compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the various substituents are defined herein, methods of using said compounds, and pharmaceutical compositions containing said compounds.

**Declarations under Rule 4.17:**

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

Published:

- with international search report (Art. 21(3))